Literature DB >> 8866695

An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice.

B Kest1, C E Lee, G L McLemore, C E Inturrisi.   

Abstract

Pharmacological data from several laboratories support a modulatory role for the delta opioid receptor in morphine analgesia, tolerance, and physical dependence. We examined the role of the delta opioid receptor in these processes using an in vivo antisense strategy in mice. Intracerebroventricular administration of a 20mer antisense or a mismatch control oligodeoxynucleotide (ODN) targeting the mRNA of the cloned delta opioid receptor (DOR-1) for 3 days did not affect baseline nociceptive thresholds or morphine analgesia compared to untreated or saline-treated mice. However, dose-response studies indicate that the induction of morphine tolerance following 3 days of chronic morphine administration was blocked in antisense but not mismatch ODN or saline-treated mice. Antisense ODN treatment also blocked the development of acute morphine dependence, whereas similar protection was not afforded to mice treated with saline or mismatch ODN. This study demonstrates the relevance of the cloned DOR-1 in morphine tolerance and dependence and provides new evidence for a modulatory role of the delta opioid receptor using this novel approach.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8866695     DOI: 10.1016/0361-9230(95)02092-6

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  44 in total

1.  Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.

Authors:  C Wahlestedt; P Salmi; L Good; J Kela; T Johnsson; T Hökfelt; C Broberger; F Porreca; J Lai; K Ren; M Ossipov; A Koshkin; N Jakobsen; J Skouv; H Oerum; M H Jacobsen; J Wengel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells.

Authors:  A Alt; M J Clark; J H Woods; J R Traynor
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  How to design an opioid drug that causes reduced tolerance and dependence.

Authors:  Amy Chang Berger; Jennifer L Whistler
Journal:  Ann Neurol       Date:  2010-05       Impact factor: 10.422

4.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

Review 5.  Acute opioid dependence: characterizing the early adaptations underlying drug withdrawal.

Authors:  Andrew C Harris; Jonathan C Gewirtz
Journal:  Psychopharmacology (Berl)       Date:  2005-02-05       Impact factor: 4.530

6.  Discovery of novel triazole-based opioid receptor antagonists.

Authors:  Qiang Zhang; Susan M Keenan; Youyi Peng; Anil C Nair; Seong Jae Yu; Richard D Howells; William J Welsh
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

Review 7.  Opioid ligands with mixed mu/delta opioid receptor interactions: an emerging approach to novel analgesics.

Authors:  Subramaniam Ananthan
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

8.  Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo.

Authors:  Jyoti Joshi Mundra; Alexandra Terskiy; Richard D Howells
Journal:  J Pharmacol Exp Ther       Date:  2012-04-26       Impact factor: 4.030

9.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

10.  Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.

Authors:  Jessica H Harvey; Darcie H Long; Pamela M England; Jennifer L Whistler
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.